12. COST-UTILITY ANALYSIS OF THE USE OF PEMBROLIZUMAB AS POST NEPHRECTOMY ADJUVANT TREATMENT IN ADULT SUBJECTS WITH RENAL CELL CARCINOMA IN THE ITALIAN CONTEXT

[featured_image]

Download

Download is available until [expire_date]

Versione
Download 0
Dimensioni file 587.09 KB
Conteggio file 1
Data di creazione Gennaio 7, 2025
Ultimo aggiornamento Gennaio 7, 2025

12. COST-UTILITY ANALYSIS OF THE USE OF PEMBROLIZUMAB AS POST NEPHRECTOMY ADJUVANT TREATMENT IN ADULT SUBJECTS WITH RENAL CELL CARCINOMA IN THE ITALIAN CONTEXT